Literature DB >> 2030331

Action of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide on the rat vascular system: effects on blood pressure and receptor binding.

K A Nandha1, M A Benito-Orfila, D M Smith, M A Ghatei, S R Bloom.   

Abstract

The N-terminal fragment (PACAP 27) of the novel neuropeptide, pituitary adenylate cyclase-activating polypeptide 38 (PACAP 38), has 68% homology with vasoactive intestinal polypeptide (VIP). The administration of bolus doses of PACAP 38 and its 27 amino acid N-terminal fragment (PACAP 27) caused a rapid but transient dose-dependent hypotensive effect in the anaesthetized rat. The amplitude and duration of the response obtained by PACAP 38 was comparable with VIP whereas PACAP 27 was three times less potent than VIP. Furthermore, radioreceptor binding studies demonstrated that 125I-labelled PACAP 27 and 125I-labelled VIP bound to membranes prepared from blood vessels. Both PACAP 27 and VIP were capable of displacing the other from these binding sites. We propose that the hypotensive effect is via the same receptor type.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2030331     DOI: 10.1677/joe.0.1290069

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  10 in total

1.  Pituitary adenylate cyclase activating peptides relax human pulmonary arteries by opening of KATP and KCa channels.

Authors:  L Bruch; S Rubel; A Kästner; K Gellert; M Gollasch; C Witt
Journal:  Thorax       Date:  1998-07       Impact factor: 9.139

2.  Pituitary adenylate cyclase-activating polypeptide (PACAP) induces relaxations of peripheral and cerebral arteries, which are differentially impaired by aging.

Authors:  Zoltan Vamos; Ivan Ivic; Peter Cseplo; Gabor Toth; Andrea Tamas; Dora Reglodi; Akos Koller
Journal:  J Mol Neurosci       Date:  2014-06-19       Impact factor: 3.444

3.  Comparative effects of PACAP and VIP on pancreatic endocrine secretions and vascular resistance in rat.

Authors:  G Bertrand; R Puech; Y Maisonnasse; J Bockaert; M M Loubatières-Mariani
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

4.  Novel, biocompatible, and disease modifying VIP nanomedicine for rheumatoid arthritis.

Authors:  Varun Sethi; Israel Rubinstein; Antonina Kuzmis; Helen Kastrissios; James Artwohl; Hayat Onyuksel
Journal:  Mol Pharm       Date:  2013-01-23       Impact factor: 4.939

5.  Pituitary adenylate cyclase activating polypeptide is a potent vasodilator and oedema potentiator in rabbit skin in vivo.

Authors:  J B Warren; S W Larkin; M Coughlan; R Kajekar; T J Williams
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

Review 6.  Inhibitory effect of PACAP on caspase activity in neuronal apoptosis: a better understanding towards therapeutic applications in neurodegenerative diseases.

Authors:  Agnieszka Dejda; Valérie Jolivel; Steve Bourgault; Tommy Seaborn; Alain Fournier; Hubert Vaudry; David Vaudry
Journal:  J Mol Neurosci       Date:  2008-05-28       Impact factor: 3.444

7.  Regional haemodynamic responses to pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide in conscious rats.

Authors:  S M Gardiner; T Rakhit; P A Kemp; J E March; T Bennett
Journal:  Br J Pharmacol       Date:  1994-02       Impact factor: 8.739

8.  The pituitary adenylate cyclase-activating polypeptide is a physiological inhibitor of platelet activation.

Authors:  Kathleen Freson; Hitoshi Hashimoto; Chantal Thys; Christine Wittevrongel; Sophie Danloy; Yoshiko Morita; Norihito Shintani; Yoshiaki Tomiyama; Jos Vermylen; Marc F Hoylaerts; Akemichi Baba; Chris Van Geet
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

9.  Pituitary Adenylate Cyclase-Activating Polypeptide-27 (PACAP-27) in the Thalamic Paraventricular Nucleus Is Stimulated by Ethanol Drinking.

Authors:  Anuranita Gupta; Andrew T Gargiulo; Genevieve R Curtis; Preeti S Badve; Surya Pandey; Jessica R Barson
Journal:  Alcohol Clin Exp Res       Date:  2018-07-20       Impact factor: 3.455

10.  VPAC1 receptors play a dominant role in PACAP-induced vasorelaxation in female mice.

Authors:  Ivan Ivic; Marta Balasko; Balazs D Fulop; Hitoshi Hashimoto; Gabor Toth; Andrea Tamas; Tamas Juhasz; Akos Koller; Dora Reglodi; Margit Solymár
Journal:  PLoS One       Date:  2019-01-25       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.